TWO MAJOR, DISRUPTIVE CHANGES lie ahead for both clinical laboratories and anatomic pathology group practices. Each disruptive factor has nothing to do with how payers select in-network labs or reimburse for lab testing services.
Rather, one of these two major changes involves fundamental advances in the diagnostic technologies used by labs to diagnose disease and guide physicians. The other major change centers upon control of the lab testing marketplace by a new group of deep-pocketed corporate entities.
These important developments will be discussed in detail at the upcoming 23rd annual Executive War College on Lab and Pathology Management, which takes place on May 1-2 in New Orleans. (Visit: www.executivewarcollege.com.)
At the general session on Wednesday, May 2, keynote Speaker Mara Aspinall, CEO of Health Catalysts in Boston, Mass., will take up the first major disruptive trend. She will discuss how the flood of data from gene sequencing and other fast-developing sources of biomarkers is poised to transform how laboratories are organized. Her presentation is titled, “Big Changes in Clinical Diagnostics: Why Your Lab is Now in the Information Business, with a Wet Lab on the Side.”
The following keynote speaker will address the second major disruptive trend. William G. Morice II, MD, PhD, is Chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minn. He will explain why pharmaceutical companies are starting to pour huge dollars into clinical diagnostics. Their money is buying control of intellectual property, not to mention ownership of lab companies with proprietary, high-value genetic and molecular tests.
Morice’s presentation has the title, “How Pharma Money and Private Equity Investors Are Poised to Use the Coming Generation of Genetic Testing and Clinical Diagnostics to Reshape the Lab Test Marketplace.”
Another major topic at this year’s Executive War College is the actual decline in Medicare revenue experienced by both hospital/health system labs and independent labs since the Part B lab test fee cuts took effect on Jan. 1. Collectively, just these three topics will have immense value in helping lab executives and pathologists develop effective strategies that allow their labs to deliver innovative lab test services while preserving financial stability.